Renaissance Technologies LLC recently announced the acquisition of new stake in Viveve Medical Inc. (NASDAQ:VIVE). The institutional investor has increased its shareholding in the Healthcare company by 8.72% to 32400.0 shares with purchase of 2600.0 shares. This fresh investment now brings its stake to 0.30% valued currently at $13770.0.
With over 0.74 million Viveve Medical Inc. (VIVE) shares trading Friday and a closing price of $0.86 on the day, the dollar volume was approximately $0.64 million. The shares have shown a positive half year performance of 40.13% and its price on 01/13/23 gained nearly 5.72%. Currently, there are 10.72M common shares owned by the public and among those 10.72M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for VIVE have a consensus price objective of $6.25. The analysts have set the share’s price value over the next 12 months at a high of $6.25 and a low of $6.25. The average price target is 81.58% above its recent price level and an upside to the estimated low will see the stock gain 86.24% over that period. But an upside of 86.24% will see the stock hit the forecast high price target while median target price for the stock is $6.25.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Viveve Medical Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Series Total Market Inde. Vanguard Extended Market Index Fu owns 0.11 million shares of the company’s stock, all valued at over $48455.0. Fidelity Series Total Market Inde now owns shares totaling to 0.05% of the shares outstanding.
Shares of Viveve Medical Inc. (NASDAQ: VIVE) opened at $0.9018, up $0.09 from a prior closing price of $0.81. However, the script later moved the day high at 0.9998, up 5.72%. The company’s stock has a 5-day price change of 30.34% and 46.98% over the past three months. VIVE shares are trading 102.38% year to date (YTD), with the 12-month market performance down to -26.49% lower. It has a 12-month low price of $0.35 and touched a high of $1.24 over the same period. VIVE has an average intraday trading volume of 74.32K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 62.69%, 76.87%, and 21.97% respectively.
Institutional ownership of Viveve Medical Inc. (NASDAQ: VIVE) shares accounts for 9.30% of the company’s 10.72M shares outstanding. Mutual fund holders own 1.54%, while other institutional holders and individual stakeholders account for 3.59% and 0.00% respectively.
It has a market capitalization of $8.70M and a beta (3y monthly) value of 0.41. The earnings-per-share (ttm) stands at -$2.65. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.93% over the week and 18.77% over the month.
Analysts forecast that Viveve Medical Inc. (VIVE) will achieve an EPS of -$0.62 for the current quarter, -$0.47 for the next quarter and -$1.6 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.62 while analysts give the company a high EPS estimate of -$0.62. Comparatively, EPS for the current quarter was -$0.72 a year ago. Earnings per share for the fiscal year are expected to increase by 84.00%, and 37.30% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Viveve Medical Inc. (VIVE) as a “Strong Buy” at a consensus score of 1.50. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the VIVE, a number of firms have released research notes about the stock. Alliance Global Partners stated their Buy rating for the stock in a research note on January 29, 2021, with the firm’s price target at $10.75. Stifel coverage for the Viveve Medical Inc. (VIVE) stock in a research note released on July 23, 2019 offered a Hold rating with a price target of $1. Stifel on their part issued Buy rating on April 17, 2018.
